公开(公告)号：US5418154A

公开(公告)日：1995-05-23

申请号：US997770

申请日：1992-12-24

Applicant: Patrick Aebischer ,  John F. Mills ,  Lars Wahlberg ,  Edward J. Doherty ,  Patrick A. Tresco

Inventor： Patrick Aebischer ,  John F. Mills ,  Lars Wahlberg ,  Edward J. Doherty ,  Patrick A. Tresco

IPC: A61F2/02 ,  A61J3/07 ,  A61K9/00 ,  A61K9/48 ,  A61K9/50 ,  A61K35/12 ,  A61K35/22 ,  A61K35/30 ,  A61M31/00 ,  B01J13/02 ,  B01J13/04 ,  C12N5/00 ,  C12N5/071 ,  C12N5/0793 ,  C12N11/04 ,  C12N11/08

CPC classification number: A61K9/0092 ,  A61F2/022 ,  A61J3/07 ,  A61K35/22 ,  A61K35/30 ,  A61K9/0024 ,  A61K9/0085 ,  A61K9/4816 ,  A61K9/4833 ,  A61K9/5089 ,  A61M31/002 ,  B01J13/02 ,  B01J13/04 ,  C12N11/04 ,  C12N11/08 ,  C12N5/0012 ,  C12N5/0614 ,  C12N5/0619 ,  A61M2210/0687 ,  A61M2210/0693 ,  C12N2533/30 ,  Y10S530/817

Abstract: Elongated seamless capsules containing biological material are prepared by a method in which a coagulant, which includes a cell suspension or other biologically active factor, and a polymeric casting solution are extruded through a common extrusion port having at least two concentric bores, such that the coagulant is extruded through the inner bore and the polymeric casting solution is extruded through the outer bore. The method involves initiating extrusion of the coagulant subsequent to initiating delivery of the casting solution through the respective bores to form a capsule having a curved and smooth leading edge shape. Delivery of the coagulant is then shut off, and extrusion of the casting solution is terminated either immediately or after some predetermined time.

Abstract translation: 包含生物材料的细长无缝胶囊通过以下方法制备，其中包括细胞悬浮液或其它生物活性因子的凝结剂和聚合物浇铸溶液通过具有至少两个同心孔的共同挤出口挤出，使得凝结剂 通过内孔挤出，并且聚合物浇铸溶液通过外孔挤出。 该方法包括在引发浇铸溶液通过相应的孔之后引发凝结剂的挤出，以形成具有弯曲且光滑的前缘形状的胶囊。 然后关闭凝结剂的输送，并且立即或在一些预定时间之后终止浇注溶液的挤出。

公开(公告)号：US5092871A

公开(公告)日：1992-03-03

申请号：US600021

申请日：1990-11-30

Applicant: Patrick Aebischer ,  Paolo Dario ,  Angelo Sabatini ,  Robert F. Valentini

Inventor： Patrick Aebischer ,  Paolo Dario ,  Angelo Sabatini ,  Robert F. Valentini

IPC: A61B17/00 ,  A61B17/11 ,  A61F2/00 ,  A61L31/04 ,  A61L31/14

CPC classification number: A61L31/14 ,  A61B17/1128 ,  A61L31/04 ,  A61L31/048 ,  A61B17/00491 ,  A61B2017/00004 ,  A61F2002/30235 ,  A61F2230/0069 ,  A61L2430/32 ,  Y10S623/92 ,  Y10S977/908

Abstract: A medical device is disclosed for use in regenerating a severed nerve, including a tubular, biocompatible, electrically-charged membrane or guidance channel, having openings adapted to receive the ends of the severed nerve and defining a lumen through which the nerve can regenerate. The electrically-charged membrane can further include a polymeric electret material that is electrically poled. A method for repairing a severed nerve is also disclosed and includes placing severed nerve ends in proximity to each other within the lumen of the guidance channel of the present invention and securing the nerve ends to the device.

Abstract translation: 公开了用于再生切断的神经的医疗装置，其包括管状的，生物相容的，带电荷的膜或引导通道，其具有适于接收切断的神经的端部并限定神经可再生的内腔的开口。 带电膜可以进一步包括电极化的聚合物驻极体材料。 还公开了修复切断的神经的方法，并且包括在本发明的引导通道的内腔内彼此靠近地设置切断的神经末端并将神经末端固定到该装置。

公开(公告)号：US5030225A

公开(公告)日：1991-07-09

申请号：US621081

申请日：1990-11-30

Applicant: Patrick Aebischer ,  Robert F. Valentini

Inventor： Patrick Aebischer ,  Robert F. Valentini

IPC: A61B17/00 ,  A61B17/11 ,  A61F2/00 ,  A61L31/04 ,  A61L31/14

CPC classification number: A61L31/14 ,  A61B17/1128 ,  A61L31/04 ,  A61L31/048 ,  A61N1/0556 ,  A61N1/36103 ,  A61B17/00491 ,  A61B2017/00004 ,  A61F2002/30235 ,  A61F2230/0069 ,  A61L2430/32 ,  Y10S977/908

Abstract: A medical device is disclosed for use in regenerating a severed nerve. The device includes an implantable, tubular, electrically-charged membrane having openings adapted to receive the ends of the severed nerve and a lumen having a diameter ranging from about 0.5 millimeters to about 2.0 centimeters to permit regeneration of the nerve therethrough. The membrane is fabricated such that an electric charge is exhibited at the inner membrane surface to stimulate regeneration by axonal sprouting and process extension. Also disclosed are methods for repairing a severed nerve and for preparing a medical device for use in regeneration of a severed nerve.

Abstract translation: 公开了用于再生切断的神经的医疗装置。 该装置包括可植入的，管状带电的膜，其具有适于接纳切断的神经的端部的开口和具有约0.5毫米至约2.0厘米的直径的内腔，以允许神经通过其再生。 制造膜，使得在内膜表面显示电荷，以通过轴突发芽和加工延伸来刺激再生。 还公开了修复切断的神经和用于制备用于再次切断的神经的医疗装置的方法。

公开(公告)号：US5011486A

公开(公告)日：1991-04-30

申请号：US273236

申请日：1988-11-18

Applicant: Patrick Aebischer ,  Anastassios N. Salessiotis

Inventor： Patrick Aebischer ,  Anastassios N. Salessiotis

IPC: A61L31/04 ,  A61L31/10 ,  A61L31/14 ,  A61L31/16

CPC classification number: A61L31/16 ,  A61L31/047 ,  A61L31/048 ,  A61L31/10 ,  A61L31/146 ,  A61L2300/252 ,  A61L2300/412 ,  A61L2300/414 ,  A61L2430/32

Abstract: Medical devices and methods employing biocompatible polymers and nerve growth-enhancing active factors are disclosed for use as guidance channels for regenerating nerves. The devices are formed from a porous, tubular membrane containing active factor incorporated within the membrane and having openings adapted to receive the ends of the severed nerve. In one aspect of the invention, the membrane has an impermeable, outer membrane surface and a porous, inner membrane surface through which the active factor can diffuse and which defines the boundary of a lumen through which said nerve may regenerate. Methods for fabricating such devices are also disclosed.

Abstract translation: 公开了使用生物相容性聚合物和神经生长增强活性因子的医疗装置和方法用作神经再生的引导通道。 该装置由多孔的管状膜形成，该多孔的管状膜含有并入膜内的活性因子并且具有适于接收切断的神经的末端的开口。 在本发明的一个方面，所述膜具有不可透过的外膜表面和多孔的内膜表面，所述活性因子可通过所述内膜表面扩散并限定所述神经可再生的内腔的边界。 还公开了制造这种装置的方法。

公开(公告)号：US20110106062A1

公开(公告)日：2011-05-05

申请号：US12940090

申请日：2010-11-05

Applicant: Osiris Marroquin ,  Patrick Aebischer ,  Maurizio Molinari ,  Nicolas Bouche

Inventor： Osiris Marroquin ,  Patrick Aebischer ,  Maurizio Molinari ,  Nicolas Bouche

IPC: A61M37/00

CPC classification number: A61M5/14276 ,  A61K9/0024 ,  A61K9/0085 ,  A61K9/0092

Abstract: The present invention is directed to devices and methods for in situ delivering an antibody or a fragment thereof to a host. In particular, the invention relates to devices and methods for in situ delivering an antibody or a fragment thereof to patient suffering for a neurodegenerative disorder or other diseases treated by antibody administration.

Abstract translation: 本发明涉及将抗体或其片段原位递送至宿主的装置和方法。 特别地，本发明涉及将抗体或其片段原位递送给患有神经退行性疾病或通过抗体给药治疗的其它疾病的患者的装置和方法。

公开(公告)号：US6027721A

公开(公告)日：2000-02-22

申请号：US650726

申请日：1996-05-20

Applicant: Joseph P. Hammang ,  Patrick Aebischer

Inventor： Joseph P. Hammang ,  Patrick Aebischer

IPC: A61K9/48 ,  A61K48/00 ,  C12N15/85 ,  C12N15/00

CPC classification number: A61K48/00

Abstract: Methods and devices are provided for gene therapy using encapsulated packaging cell lines to deliver viral particles carrying at least one heterologous gene encoding at least one biologically active molecule.

Abstract translation: 提供了使用包封的包装细胞系进行基因治疗的方法和装置，以递送携带至少一种编码至少一种生物活性分子的异源基因的病毒颗粒。

公开(公告)号：US5935849A

公开(公告)日：1999-08-10

申请号：US279773

申请日：1994-07-20

Applicant: Malcolm Schinstine ,  Molly S. Shoichet ,  Frank T. Gentile ,  Joseph P. Hammang ,  Laura M. Holland ,  Brian M. Cain ,  Edward J. Doherty ,  Shelley R. Winn ,  Patrick Aebischer

Inventor： Malcolm Schinstine ,  Molly S. Shoichet ,  Frank T. Gentile ,  Joseph P. Hammang ,  Laura M. Holland ,  Brian M. Cain ,  Edward J. Doherty ,  Shelley R. Winn ,  Patrick Aebischer

IPC: A01K67/027 ,  A61K48/00 ,  A61L27/00 ,  A61L27/18 ,  A61L27/22 ,  A61L27/38 ,  C07K14/82 ,  C12N5/00 ,  C12N5/10 ,  C12N15/09 ,  C12N15/12

CPC classification number: A61L27/3839 ,  A61L27/18 ,  A61L27/227 ,  C07K14/82 ,  C12N5/0012 ,  C12N5/0068 ,  A61K48/00 ,  C12N2510/00 ,  C12N2510/04 ,  C12N2533/30 ,  C12N2533/54 ,  C12N2533/74

Abstract: This invention relates to methods and compositions of controlling cell distribution within a bioartificial organ by exposing the cells to a treatment that inhibits cell proliferation, promotes cell differentiation, or affects cell attachment to a growth surface within the bioartificial organ. Such treatments include (1) genetically manipulating cells, (2) exposing the cells to a proliferation-inhibiting compound or a differentiation-inducing compound or removing the cells from exposure to a proliferation-stimulating compound or a differentiation-inhibiting compound; exposing the cells to irradiation, and (3) modifying a growth surface of the BAO with ECM molecules, molecules affecting cell proliferation or adhesion, or an inert scaffold, or a combination thereof. These treatments may be used in combination.

Abstract translation: 本发明涉及通过将细胞暴露于抑制细胞增殖，促进细胞分化或影响细胞附着于生物人造器官内的生长表面的处理来控制生物人造器官内的细胞分布的方法和组合物。 这样的处理包括（1）遗传操纵细胞，（2）将细胞暴露于增殖抑制化合物或分化诱导化合物，或除去细胞暴露于增殖刺激化合物或分化抑制化合物; 使细胞暴露于照射，和（3）用ECM分子修饰BAO的生长表面，影响细胞增殖或粘附的分子，或惰性支架或其组合。 这些处理可以组合使用。

公开(公告)号：US5869077A

公开(公告)日：1999-02-09

申请号：US449562

申请日：1995-05-24

Applicant: Keith E. Dionne ,  Dwaine F. Emerich ,  Diane Hoffman ,  Paul R. Sanberg ,  Lisa Christenson ,  Orion D. Hegre ,  David W. Scharp ,  Paul E. Lacy ,  Patrick Aebischer ,  Alfred V. Vasconcellos ,  Michael J. Lysaght ,  Frank T. Gentile

Inventor： Keith E. Dionne ,  Dwaine F. Emerich ,  Diane Hoffman ,  Paul R. Sanberg ,  Lisa Christenson ,  Orion D. Hegre ,  David W. Scharp ,  Paul E. Lacy ,  Patrick Aebischer ,  Alfred V. Vasconcellos ,  Michael J. Lysaght ,  Frank T. Gentile

IPC: A61F2/02 ,  A61K9/00 ,  A61K9/48 ,  A61K9/50 ,  A61K35/12 ,  A61K35/30 ,  A61K35/39 ,  A61K38/18 ,  A61K39/395 ,  A61K47/36 ,  A61K48/00 ,  A61L27/00 ,  C12N5/00 ,  C12N5/071 ,  C12N5/077

CPC classification number: A61K9/0092 ,  A61K35/12 ,  A61K35/30 ,  A61K35/39 ,  A61K38/185 ,  A61K48/00 ,  A61K9/0024 ,  A61K9/4816 ,  C12N5/0012 ,  C12N5/0062 ,  C12N5/0614 ,  C12N5/0656 ,  C12N5/0677 ,  A61K2035/126 ,  A61K2035/128 ,  C12N2510/02 ,  Y10S514/814 ,  Y10S514/866

Abstract: A method for treating diabetes in a patient comprising subcutaneously implanting in the patient at least one immunoisolatory vehicle comprising a core comprising a volume of at least 1 .mu.l and at least about 10.sup.4 living cells which secrete insulin, said cells being dispersed in a biocompatible matrix comprising a hydrogel or extracellular matrix components, and a surrounding external jacket of a biocompatible thermoplastic or hydrogel free of said cells projecting externally thereof, said jacket being permselective and immunoisolatory, said jacket having a molecular weight cutoff permitting passage of molecules between the patient and core through said jacket wherein the insulin is released from the immunoisolatory vehicle into the patient's body to treat diabetes.

Abstract translation: 一种用于治疗患者的糖尿病的方法，包括在患者体内皮下植入至少一种免疫隔离性载体，所述至少一种免疫隔离载体包含至少含有至少1μl的体积和分泌胰岛素的至少约104个活细胞的核，所述细胞分散在生物相容性基质 包括水凝胶或细胞外基质组分，以及不含所述细胞从外部突出的生物相容性热塑性或水凝胶的外围护套，所述护套是选择性选择性的和免疫型的，所述护套具有分子量截留允许分子在患者和核心之间通过 通过所述护套，其中将胰岛素从免疫免疫介质释放到患者体内以治疗糖尿病。

公开(公告)号：US5858747A

公开(公告)日：1999-01-12

申请号：US447810

申请日：1995-05-23

Applicant: Malcolm Schinstine ,  Molly S. Shoichet ,  Frank T. Gentile ,  Joseph P. Hammang ,  Laura M. Holland ,  Brian M. Cain ,  Edward J. Doherty ,  Shelley R. Winn ,  Patrick Aebischer

Inventor： Malcolm Schinstine ,  Molly S. Shoichet ,  Frank T. Gentile ,  Joseph P. Hammang ,  Laura M. Holland ,  Brian M. Cain ,  Edward J. Doherty ,  Shelley R. Winn ,  Patrick Aebischer

IPC: A01K67/027 ,  A61K48/00 ,  A61L27/00 ,  A61L27/18 ,  A61L27/22 ,  A61L27/38 ,  C07K14/82 ,  C12N5/00 ,  C12N5/10 ,  C12N15/09 ,  C12N15/12 ,  C12N11/04 ,  C12N5/06 ,  C12N5/08 ,  C12N11/02

CPC classification number: C12N5/0068 ,  A61L27/18 ,  A61L27/227 ,  A61L27/383 ,  A61L27/3834 ,  A61L27/3839 ,  A61L27/3895 ,  C07K14/82 ,  A61K48/00 ,  C12N2510/00 ,  C12N2510/04 ,  C12N2533/30 ,  C12N2533/54 ,  C12N2533/74

Abstract: Methods and compositions are provided for controlling cell distribution within an implantable bioartificial organ by exposing the cells to a treatment that inhibits cell proliferation, promotes cell differentiation, or affects cell attachment to a growth surface within the bioartificial organ. Such treatments include (1) genetically manipulating cells, (2) exposing the cells to a proliferation-inhibiting compound or a differentiation-inducing compound or removing the cells from exposure to a proliferation-stimulating compound or a differentiation-inhibiting compound; exposing the cells to irradiation, and (3) modifying a growth surface of the bioartificial organ with extracellular matrix molecules, molecules affecting cell proliferation or adhesion, or an inert scaffold, or a combination thereof. These treatments may be used in combination. The bioartificial organ typically has a semipermeable membrane encapsulating a cell-containing core, and is preferably immunoisolatory. Cells can be grown on microcarriers and then loaded into the bioartificial organ. The microcarriers may be coated with an extracellular matrix component such as collagen to cause decreased cell proliferation or increased cell differentiation. Microcarriers containing cells can be suspended in a proliferation inhibiting hydrogel matrix prior to encapsulation.

Abstract translation: 提供了用于通过将细胞暴露于抑制细胞增殖，促进细胞分化或影响细胞附着于生物人造器官内的生长表面的处理来控制可植入的生物人造器官内的细胞分布的方法和组合物。 这样的处理包括（1）遗传操纵细胞，（2）将细胞暴露于增殖抑制化合物或分化诱导化合物，或除去细胞暴露于增殖刺激化合物或分化抑制化合物; 将细胞暴露于照射下，和（3）用细胞外基质分子，影响细胞增殖或粘附的分子，或惰性支架或其组合修饰生物人造器官的生长表面。 这些处理可以组合使用。 生物人造器官通常具有包封含细胞核的半透膜，并且优选地是免疫隔离的。 细胞可以在微载体上生长，然后装入生物人造器官。 微载体可以用细胞外基质组分如胶原包被，以引起细胞增殖减少或细胞分化增加。 含有细胞的微载体可以在包封之前悬浮于增殖抑制水凝胶基质中。

公开(公告)号：US5800829A

公开(公告)日：1998-09-01

申请号：US449274

申请日：1995-05-24

Applicant: Keith E. Dionne ,  Dwaine F. Emerich ,  Diane Hoffman ,  Paul R. Sanberg ,  Lisa Christenson ,  Orion D. Hegre ,  David W. Scharp ,  Paul E. Lacy ,  Patrick Aebischer ,  Alfred V. Vasconcellos ,  Michael J. Lysaght ,  Frank T. Gentile

Inventor： Keith E. Dionne ,  Dwaine F. Emerich ,  Diane Hoffman ,  Paul R. Sanberg ,  Lisa Christenson ,  Orion D. Hegre ,  David W. Scharp ,  Paul E. Lacy ,  Patrick Aebischer ,  Alfred V. Vasconcellos ,  Michael J. Lysaght ,  Frank T. Gentile

IPC: A61K9/00 ,  A61K35/12 ,  A61K9/50 ,  A61K9/14

CPC classification number: A61K9/0092 ,  A61K9/0024 ,  A61K2035/126 ,  A61K2035/128 ,  C12N2510/00

Abstract: A method of making an immunoisolatory vehicle comprised of a core comprising living cells dispersed in a biocompatible matrix is disclosed, the cells being capable of secreting a biologically active product or of providing a metabolic or immunologic function to an individual, and an external jacket surrounding said core which is a biocompatible, permselective thermoplastic or hydrogel, said jacket being free of said cells, comprising coextruding a suspension comprising said cells dispersed in a precursor matrix material comprising extracellular matrix components or a biocompatible hydrogel precursor, and a solution of a biocompatible jacket precursor from a nested dual-bore extrusion nozzle, wherein the suspension of (a) is coextruded from the inner bore and the solution of (b) is coextruded from the outer bore of the nozzle, to form said jacket as the solution of (b) and the suspension of (a) arc coextruded; and exposing the vehicle to a treatment that forms a core comprising a volume of at least 1 .mu.l and at least 10.sup.4 cells and comprising a biocompatible matrix from the precursor matrix of solution (a).

Abstract translation: 公开了一种制备由包含分散在生物相容性基质中的活细胞的核心组成的免疫隔离性载体的方法，所述细胞能够分泌生物活性产物或向个体提供代谢或免疫功能，以及围绕所述 核心，其是生物相容的选择性热塑性或水凝胶，所述护套不含所述细胞，包括共挤出包含分散在包含细胞外基质组分或生物相容性水凝胶前体的前体基质材料中的所述细胞的悬浮液，以及生物相容性护套前体 从嵌套的双孔挤出喷嘴中，其中（a）的悬浮液从内孔共挤出并且（b）的溶液从喷嘴的外孔共挤出，形成作为（b）的溶液的所述夹套， 和（a）电弧共挤出的悬浮液; 并将载体暴露于形成包含体积至少为1μl和至少104个细胞并且包含来自溶液（a）的前体基质的生物相容性基质的核心的处理。